Synthesis and activity of a potent, specific azabicyclo[3.3.0]-octane-based DPP II inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 2, 2007, Pages 507-510

  Danilova, Olga ^a   Li, Bei ^b   Szardenings, A Katrin ^b   Huber, Brigitte T ^a   Rosenblum, Jonathan S ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ACTIVX BIOSCIENCES INC   (United States)

Author keywords

Dipeptidyl peptidase

Indexed keywords

AX 8819; AZABICYCLO[3.3.0]OCTANE; DIPEPTIDYL PEPTIDASE II INHIBITOR; ENZYME INHIBITOR; OCTANE; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LYMPHOCYTE;

APOPTOSIS; AZA COMPOUNDS; CELL DEATH; DIPEPTIDYL PEPTIDASES; HUMANS; JURKAT CELLS; KINETICS; LYMPHOCYTES; OCTANES; PROTEASE INHIBITORS;

EID: 33846101646     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.10.012     Document Type: Article

References (27)

1. Rosenblum J.S., and Kozarich J.W. Curr. Opin. Chem. Biol. 7 (2003) 496
2. Augustyns K., Van der Veken P., Senten K., and Haemers A. Curr. Med. Chem. 12 (2005) 971
3. Ahren B. Expert Opin. Investig. Drugs 15 (2006) 431
4. Deacon C.F. Regul. Pept. 128 (2005) 117
5. Leiting B., Pryor K.D., Wu J.K., Marsilio F., Patel R.A., Craik C.S., Ellman J.A., Cummings R.T., and Thornberry N.A. Biochem. J. 371 (2003) 525
6. Edosada C.Y., Quan C., Wiesmann C., Tran T., Sutherlin D., Reynolds M., Elliott J.M., Raab H., Fairbrother W., and Wolf B.B. J. Biol. Chem. 281 (2006) 7437
7. Sun S., Albright C.F., Fish B.H., George H.J., Selling B.H., Hollis G.F., and Wynn R. Protein Expr. Purif. 24 (2002) 274
8. Underwood R., Chiravuri M., Lee H., Schmitz T., Kabcenell A.K., Yardley K., and Huber B.T. J. Biol. Chem. 274 (1999) 34053
9. Shariat-Madar Z., Mahdi F., and Schmaier A.H. J. Biol. Chem. 277 (2002) 17962
10. Duysen E.G., Li B., Xie W., Schopfer L.M., Anderson R.S., Broomfield C.A., and Lockridge O. J. Pharmacol. Exp. Ther. 299 (2001) 528
11. Chen Y.S., Chien C.H., Goparaju C.M., Hsu J.T., Liang P.H., and Chen X. Protein Expr. Purif. 35 (2004) 142
12. Olsen C., and Wagtmann N. Gene 299 (2002) 185
13. Chiravuri M., Agarraberes F., Mathieu S.L., Lee H., and Huber B.T. J. Immunol. 165 (2000) 5695
14. Chiravuri M., Lee H., Mathieu S.L., and Huber B.T. J. Biol. Chem. 275 (2000) 26994
15. Chiravuri M., Schmitz T., Yardley K., Underwood R., Dayal Y., and Huber B.T. J. Immunol. 163 (1999) 3092
16. Danilov A.V., Klein A.K., Lee H.J., Baez D.V., and Huber B.T. Br. J. Haematol. 128 (2005) 472
17. Shreder K.R., Wong M.S., Corral S., Yu Z., Winn D.T., Wu M., Hu Y., Nomanbhoy T., Alemayehu S., Fuller S.R., Rosenblum J.S., and Kozarich J.W. Bioorg. Med. Chem. Lett. 15 (2005) 4256
18. Senten K., Van der Veken P., De Meester I., Lambeir A.M., Scharpe S., Haemers A., and Augustyns K. J. Med. Chem. 46 (2003) 5005
19. Senten K., Van Der Veken P., De Meester I., Lambeir A.M., Scharpe S., Haemers A., and Augustyns K. J. Med. Chem. 47 (2004) 2906
20. Ennis M., Hoffman R., Ghazal N., Old D., and Mooney P. J. Org. Chem. 61 (1996) 5813
21. Hu Y., Ma L., Wu M., Wong M.S., Li B., Corral S., Yu Z., Nomanbhoy T., Alemayehu S., Fuller S.R., Rosenblum J.S., Rozenkrants N., Minimo L.C., Ripka W.C., Szardenings A.K., Kozarich J.W., and Shreder K.R. Bioorg. Med. Chem. Lett. 15 (2005) 4239
22. 2, 2 mM EDTA, 10 mM KCl, 0.1% Nonidet P-40, 5 μg/ml antipain, and 5 μg/ml leupeptin) for 30 min at 4 °C. DPP activity was measured using the fluorogenic substrate AP-AFC (2 mM in 50 mM Hepes buffer, pH 7.5) on an Fmax fluorescence plate reader (Molecular Devices, Menlo Park, CA) excitation, 410 nm; emission, 510 nm. The specificity of compounds was investigated by treating untransfected HEK cells with the same concentration of compound that inhibited approximately half of the overexpressed DPP II activity (293T HEK column).
23. 6 PBMCs in 0.5 ml of culturing media were plated in 24-well flat-bottomed plates in triplicate and treated with VbP at final concentration 10 μM DMSO (vehicle control), and AX8819 at 4.4, 8.8, 22, and 44 μM final concentrations. Cells were washed twice with PBS and were stained with 2 μl AnV-Allophycocyanin (APC) in 50 μl of Annexin V binding buffer for 15 min on ice, after that 350 μl FACS buffer (phosphate-buffered saline (PBS) supplemented with 1% FBS and 0.01% sodium azide) and PI (propidium iodide 10 μg/ml) were added. Experiments were repeated at least twice. PBMCs from different individuals were used to confirm the reproducibility of results.
24. Kuhn H., Weser L., Gessner C., Hammerschmidt S., and Wirtz H. Oncol. Rep. 14 (2005) 759
25. Micheau O., Lens S., Gaide O., Alevizopoulos K., and Tschopp J. Mol. Cell. Biol. 21 (2001) 5299
26. Maes M.B., Martinet W., Schrijvers D.M., Van der Veken P., De Meyer G.R., Augustyns K., Lambeir A.M., Scharpe S., and De Meester I. Biochem. Pharmacol. 72 (2006) 70
27. Robertson J.D., Gogvadze V., Zhivotovsky B., and Orrenius S. J. Biol. Chem. 275 (2000) 32438